Alzamend neuro announces initiation date of phase ii clinical trial of al001 for treatment of alzheimer's disease to take place at massachusetts general hospital

Atlanta, march 25, 2025 (globe newswire) -- alzamend neuro, inc. (nasdaq: alzn) (“alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer's disease (“alzheimer's”), bipolar disorder (“bd”), major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”), today announced its plans to initiate a highly anticipated phase ii clinical study of al001 for treatment of patients with alzheimer's in the fourth quarter of 2025. this study follows the successful completion of a head coil by tesla dynamic coils bv, a key component of the clinical trial.
GM Ratings Summary
GM Quant Ranking